



Search for New Moenomycin Structure-Activity Relationships

Synthesis of a Trisaccharide Precursor of a Moenomycin Analogue

Olaf Ritzeler, Lothar Hennig, Matthias Findeisen, Peter Welzel*

Fakultät für Chemie und Mineralogie der Universität Leipzig

Talstr. 35, D-04103 Leipzig (Germany)

Dietrich Müller

Fakultät für Chemie der Ruhr-Universität, D-44780 Bochum (Germany)

Abstract - On the way to a trisaccharide analogue of the antibiotic moenomycin A a trisaccharide intermediate has been prepared making use of a combination of Danishefsky's sulfonamidoglycosylation and the Schmidt trichloroacetimidate procedure. © 1997, Elsevier Science Ltd. All rights reserved.

Introduction

Two characteristic members of the moenomycin family of antibiotics are the moenomycins A¹ and A₁₂² (see Figure 1). Structurally, they differ only marginally from each other. Whereas in moenomycin A unit F is derived from 4-C-methyl-D-glucuronic acid, in moenomycin A₁₂ the branching methyl group is lacking and unit F has D-galacto configuration.





Figure 1. Structures of moenomycins A and A₁₂


This seemingly simple difference has, however, important consequences in terms of structure-activity-relationships. The smallest degradation product of moenomycin A that retains full antibiotic activity is the disaccharide

analogue **1**.³ In contrast, the smallest antibioticly active degradation product of moenomycin A₁₂ is the trisaccharide derivative **3a** whereas **2** is inactive.² This result has been confirmed with synthetic compounds (**3b**⁴ and **2**⁵).



The moenomycins and structural analogues derived therefrom have been shown to specifically inhibit the transglycosylation reaction, one of the final steps in the biosynthesis of bacterial peptidoglycan.⁶ Based on experimental work, they are assumed to compete with the immediate peptidoglycan membrane-bound precursor **5**


(lipid II) for the binding site at the enzyme, most probably as a result of structural similarities.³ The conformations of **1** in solution and after binding to the enzyme are unknown because of experimental difficulties. Moenomycin and its structural analogues are amphiphilic compounds that form aggregates in aqueous solution resulting in broad-line ¹H NMR spectra.⁷ As a working model we have used a bent conformation for both **1** and lipid II (**5**). The structural similarities of these conformations are immediately evident. Why now is **1** active and the structurally closely related **2** is not? Leaving the methyl group for the moment aside, the only difference between **1** and **2** is the configuration at C-4 of unit F. One may conclude that the equatorial 4^F-OH group is a prerequisite of antibiotic activity in disaccharide analogues and that this OH group is involved in a hydrogen bond to the binding site of the enzyme. Since lipid II (**5**), the real substrate for the enzyme, carries an OR group (R≠H) at the corresponding position this oxygen function is most likely acting as a hydrogen bond acceptor. At present it is not clear whether there is but a single binding site for moenomycin-type transglycosylase inhibitors at the enzyme. If so, the function of the third sugar (C) in the active trisaccharides **3a** and **3b** might be to mimic the equatorial OH group at C-4 in unit F of **1** as a hydrogen bond acceptor. This is seen in conformation **4** which is derived from **3b** by proper alignment of ring C. In conformation **4** either an equatorial OH group at C-3 (Z) or an axial OH group at C-4 (X) could serve as the hydrogen bond acceptor in place of the equatorial 4-OH group in unit F (see arrow in formula **4**).



It is the purpose of the present and the accompanying papers to probe this speculation by experiment. We describe the synthesis and antibiotic properties of compound **6** which differs from **3b** by the replacement NHAc→OH at position 2 of ring C. In addition, synthesis of a type **4** compound with D-galacto configuration in ring C is reported in the third paper of this series. If the above considerations were correct the NHAc group in ring C of type **3** trisaccharide analogues should be of little influence as far as transglycosylase inhibition is concerned, i.e. **6** and its ring C D-galacto stereoisomer should be active.

Synthetic planning for 6 and synthesis of trisaccharide intermediate 12

The retrosynthetic analysis as indicated in formula 6 leads to three precursors: a C-E-F trisaccharide, a phosphoric acid equivalent G, and an equivalent of H-I, which can be obtained from moenomycin by degradation.⁸ For the synthesis of C-E-F a two-step approach was envisioned: (i) to use Danishefsky's sulfonamidoglycosylation procedure^{9,10} for the preparation of a disaccharide equivalent of C-E and (ii) to couple C-E to unit F. From this analysis a derivative of cellobiose as starting material for the synthesis is derived.



Octaacetylcellobiose was converted into the 1-bromo derivative¹¹ which in turn was reduced with zinc in acetic acid to provide 7a¹² (hexaacetylcellobial). 7a was treated with 2-(trimethylsilyl)ethanesulfonamide (8)^{13,10} in the presence of iodonium-di-sym-collidine perchlorate (IDCP)¹⁴ to provide sulfonamide 10a in 58% yield.




Figure 2. Temperature dependent ^1H NMR spectrum of **10a** ($\delta = 4.0$ - 6.5 region)

Whereas in **10a** ring E adopts the $^4\text{C}_1$ conformation ($J_{1\text{E},2\text{E}} = 1.5$ Hz, $J_{2\text{E},3\text{E}} = 4.2$ Hz) in the benzyl analogue **10b** obviously the $^1\text{C}_4$ conformation prevails ($J_{1\text{E},2\text{E}} = 9.9$ Hz, $J_{2\text{E},3\text{E}} = 2.9$ Hz). For the sulfonamidoglycosylation the substituents at C-1 and C-2 must be antiperiplanar. We were, therefore, interested to study the dynamic properties of both **10a** and **10b**. The results for **10a** are shown in Figure 2. Conformational equilibria have been

identified by running NMR spectra in the temperature range of -50°C to $+50^{\circ}\text{C}$. Coalescence phenomena are evident for NH and 1-H^{E} . Since 2-H^{E} does not show such a coalescence the conformational change must be a local phenomenon, and we believe that the sulfonamide group is responsible for it. A similar process has been observed for **10b**. In this case, too, a change in the ring conformation can be excluded in the temperature range investigated ($-50^{\circ}\text{C} \rightarrow 50^{\circ}\text{C}$).¹⁵ In Figure 2 the expected temperature dependence of the NH proton chemical shift is observed as well as for the water signal ($\delta \approx 5.85$ at -50°C). Interestingly, at low temperatures only a single set of resonances is observed indicating that the second conformer is present only at low concentrations. As will be described below the formation of the N-sulfonylaziridine intermediate in the Danishefsky route is not hampered by fact that **10b** exists mainly in the ${}^1\text{C}_4$ conformation with the substituents at C-1 and C-2 in a diequatorial disposition.

Danishefsky has reported that there are cases where the iodosulfonamides themselves are poor donors in glycosylation reactions. To circumvent these problems the iodosulfonamides were converted into ethyl 2-sulfonamido-2-deoxy- β -thioglycosides which then were used as glycosyl donors after activation with methyl triflate.¹⁶ We explored a different approach and converted iodosulfonamide **10b** via the sulfonylaziridine intermediate into **9** by treatment with aqueous lithium hydroxide in THF (95% yield). **9** was then submitted to the Schmidt glycosylation reaction.¹⁷ Thus, **9** reacted with trichloroacetonitrile in the presence of DBU to furnish **11** (91% yield) which on exposure to the galacturonamide derivative **12** and trimethylsilyltriflate yielded the desired trisaccharide **13** ($\alpha:\beta = 1:4$) in 60 % yield.

Interestingly, the FAB mass spectra of cellobial and its derivatives **7a** and **7b**, and of many of the benzyl protected compounds displayed peaks (formally) at M^+ and $[\text{M}-\text{H}]^+$, besides $[\text{M}+\text{H}]^+$.¹⁸ At least in the case of cellobial, **7a**, and **7b** according to MIKE analyses these ions are derived from $[\text{M}+\text{H}]^+$ by loss of a hydrogen atom and of H_2 , respectively.

EXPERIMENTAL

General

For flash chromatography (FC), see ref.¹⁹ For all other methods, see ref.². The fragments in the mass spectra are named as introduced in ref.¹. Benzyl protons and carbons of the individual benzyl group are indicated as a,b,c,... when the connectivity was determined by C,H COSY spectra, for other correlations arbitrarily the peak numbers of the ${}^{13}\text{C}$ NMR spectra are used. $\text{CH}_2(\text{a})$ and $\text{CH}_2(\text{b})$ refers to the 2-trimethylsilylethyl protecting group. If not stated otherwise the matrix for the FAB mass spectra was 3-nitrobenzylalcohol.

***N*-[3,6-Di-*O*-acetyl-4-*O*-(2,3,4,6-tetra-*O*-acetyl- β -D-glucopyranosyl)-2-deoxy-2-iodo- α -D-manno-pyranosyl]-2-(trimethylsilyl)-ethanesulfonamide (10a)**

To a stirred suspension of **7a** (509 mg, 0.91 mmol), sulfonamide **8** (178 mg, 1.02 mmol), and powdered 4 Å molecular sieves in CH₂Cl₂ (5 mL) at 40°C a solution of I(sym-coll)₂ClO₄ (789 mg, 1.68 mmol) in CH₂Cl₂ (7 mL) was added. The mixture was stirred at 40°C for 3 h and then filtered. The residue was washed with CH₂Cl₂ (4x30 mL). The combined organic solutions were washed with sat. aq. Na₂S₂O₃ (3x), with sat. aq. CuSO₄, and water. Drying (MgSO₄), filtration, solvent evaporation and MPLC (petrol - ethyl acetate 1:1) provided pure **10a** (340 mg, 58% based on consumed **7a**). 130 mg (0.23 mmol) of **7a** were recovered. - ¹H NMR (400 MHz, CDCl₃): δ = 5.31 (d, J_{1E,NH} = 10.5 Hz, NH), 5.15 (t, J_{2C,3C} = J_{3C,4C} = 9.5 Hz, 3-H^C), 5.03 (t, J_{4C,5C} = 9.5 Hz, 4-H^C), 4.90 (dd, 2-H^C), 4.69 (dd, J_{1E,2E} = 1.5 Hz, J_{2E,3E} = 4.2 Hz, 2-H^E), 4.6 (dd, J_{5C or E, 6C or E} = 4.6 Hz, J_{6C or E, 6C or E} = 12.2 Hz, 6^{C or E}-H), 4.56 (d, J_{1C,2C} = 8.1 Hz, 1-H^C), 4.42 (dd, J_{3E,4E} = 9.1 Hz, 3-H^E), 4.30 (dd, J_{5E or C, 6E or C} = 5.1 Hz, J_{6E or C, 6E or C} = 12.5 Hz, 6^{E or C}-H), 4.08 (dd, 1-H^E), 4.03 (dd, 6^{E or C}-H'), 3.96 (dd, 6^{C or E}-H'), 3.92 (t, J_{4E,5E} = 9.5 Hz, 4-H^E), 3.68 (ddd, J_{5E or C, 6E or C} = 2.2 Hz, 5-H^{E or C}), 3.62 (ddd, J_{5C or E, 6C or E} = 2.0 Hz, 5-H^{C or E}), 3.00 - 3.09 (m, CH₂(a)), 2.12 - 1.96 (6 * s, OAc signals), 0.90 - 1.10 (m, CH₂(b)), 0.00 (s, Si(CH₃)₃). - ¹³C NMR (100.6 MHz, C,H COSY, CDCl₃): δ = 170.4 - 169.0 (OAc signals), 100.5 (C-1^C), 79.5 (C-1^E), 75.2 (C-5^{C or E}), 74.6 (C-4^E), 72.6 (C-3^C), 71.7 (C-5^{E or C}), 71.4 (C-2^C), 71.0 (C-3^E), 67.9 (C-4^C), 61.9 (C-6^{E or C}), 61.3 (C-6^{C or E}), 51.8 (CH₂(a)), 38.9 (C-2^E), 20.4 - 20.7 (OAc), 10.1 (CH₂(b)), -2.2 (Si(CH₃)₃). - C₂₉H₄₆INO₁₇SSi (867.72, 867.13), FAB MS: *m/z* = 868.1 ([M+H]⁺), 740.2 ([M-H]⁺), 331 ([c]⁺).

3,6-Di-*O*-benzyl-4-*O*-(2,3,4,6-tetra-*O*-benzyl- β -D-glucopyranosyl)-1,5-anhydro-2-deoxy-D-glucopyranose (7b)

To a solution of cellobial (20.00 g, 0.07 mol) in DMSO (250 mL) sodium methylsulfinylmethide (2 mol/L in DMSO, 200 mL, 0.400 mol) was added within 1 h. Then benzyl chloride (100 mL) was added at such a rate that a reaction temperature of 40°C was maintained (3 h, colour change greenish→red-violet). After 15 h to the yellow reaction mixture first methanol (50 mL) and then ice-water (20 mL) were added. Volatiles were removed at 100°C / 10⁻² mbar. The residue was taken up in CHCl₃ (500 mL) and the solution was washed with sat. aq. NH₄Cl. After solvent evaporation to the oily residue water was added and the mixture was first sonified and then lyophilized. This process was repeated 5 times. The solidified product was purified by LC (petrol - ethyl acetate 9:1) to provide **7b** (24.83 g, 45%). - ¹H NMR (400 MHz, CDCl₃): δ = 6.39 (d, J_{1E,2E} = 6.4 Hz, 1-H^E), 4.82 (dd, partially hidden, 2-H^E), 4.52 (d, J_{1C,2C} = 7.8 Hz, 1-H^C), 4.25 - 4.20 (m, 1H), 4.16 - 4.11 (m, 1H, correlates with 7), 4.09 - 4.06 (m, 1H, correlates with 4), 3.79 (dd, 6^{C or E}-H), 3.62 - 3.58 (m, 3H, 6^{C or E}-H', CH₂-6^{E or C}), 3.55 - 3.50 (m, 2H, correlate with 15, 13), 3.40 - 3.35 (m, 2H, correlate with 14, 8), benzyl group signals at: 7.15 - 7.35 (m, Ar-H); 4.85, 4.71 (CH₂^{benzyl (f)}, AB); 4.80, 4.60 (CH₂^{benzyl (d)}, AB); 4.74, 4.47 (CH₂^{benzyl (e)}, AB); 4.54 (CH₂^{benzyl (a)}, AB); 4.43 (CH₂^{benzyl (b)}, AB); 4.45, 4.38 (CH₂^{benzyl (c)}, AB). - ¹³C-NMR (100.6 MHz, C,H COSY, DEPT, CDCl₃): δ = 144.1 (C-1^E), 102.2 (C-1^C), 99.1 (C-2^E), 84.1 (CH, 15), 81.5 (CH, 14), 77.2 (CH, 13), 75.4 (CH, 12), 74.3 (CH, 8), 72.90 (CH, 7), 71.2 (CH, 4), 68.4 (C-6^{E or C}, 2), 67.2 (C-6^{C or E}, 1), benzyl group signals at: 138.2 - 137.4 (Ar-Cⁱ's), 127.9 - 126.9 (Ar-C's), 75.1 (CH₂^{benzyl (f)}), 74.4 (CH₂^{benzyl (e)}), 74.3 (CH₂^{benzyl (d)}), 72.85 (CH₂^{benzyl (c)}), 72.7

(CH₂^{benzyl (b)}), 69.5 (CH₂^{benzyl (a)}), - C₅₄H₅₆O₉ (849.03, 848.39), FAB MS (MIKE-spectra): *m/z* = 871.2 ([M+Na]⁺), 849.0 ([M+H]⁺), 848.0 ([M+H-H⁺]⁺), 847.2 ([M+H-H₂]⁺), 741.2 ([M+H-BnOH]⁺).

***N*-[3,6-Di-*O*-benzyl-4-*O*-(2,3,4,6-tetra-*O*-benzyl-β-D-glucopyranosyl)-2-deoxy-2-iodo-α-D-mannopyranosyl]-(2-trimethylsilyl)ethanesulfonamide (10b)**

To a suspension of **7b** (20.68 g, 0.024 mol), sulfonamide **8**, and 4 Å molecular sieves (14.00 g) in CH₂Cl₂ (120 mL) solid I(sym-coll)₂ClO₄ (49.00 g, 0.104 mol) was added. The mixture was stirred at 0°C for 5 h. Work-up was performed as described for **7a**→**10a**. FC (petrol - ethyl acetate 10:1 ⇒ 3:1) furnished **10b** (18.64 g, 66%). - IR (CHCl₃): 3375 cm⁻¹ (NH). - ¹H NMR (400 MHz, H₂O COSY, CDCl₃): δ = 5.18 (t, broad, J_{1E, NH} = J_{1E, 2E} = 9.9 Hz, after NH→ND exchange: d, J_{1E, 2E} = 9.9 Hz, 1-H^E) 4.85 (d, broad, NH), 4.38 (dd, partially hidden, J_{2E, 3E} = 2.9 Hz, 2-H^E), 4.25 (d, J_{1C, 2C} = 7.7 Hz, 1-H^C), 4.23 - 4.18 (m, 5-H^C), 4.15 - 4.12 (m, 3-H^E), 3.90 - 3.84 (m, 6^C-H), 3.63 - 3.61 (m, partially hidden, 4-H^E, CH₂-6^E), 3.59 - 3.52 (m, partially hidden, 4H, including 3-H^C, 4-H^C, 6^C-H), 3.44 - 3.39 (m, J_{2C, 3C} ≈ 7.7 Hz, 2-H^C), 3.38 - 3.33 (m, 5-H^E), 3.12 - 2.92 (m, CH₂(a)), 1.02 - 0.95 (m, CH₂(b)), - 0.12 (s, TMS), benzyl group signals at: 7.30 - 7.20 (m, Ar-H); 4.88, 4.77 (CH₂^{benzyl (a)}, AB); 4.85, 4.69 (CH₂^{benzyl (b)}, AB); 4.83, 4.54 (CH₂^{benzyl (c)}, AB); 4.64, 4.51 (CH₂^{benzyl (d)}, AB); 4.54 (CH₂^{benzyl (e)}, AB); 4.42, 4.47 (CH₂^{benzyl (f)}, AB). - ¹³C NMR (100.6 MHz, C,H COSY, DEPT, CDCl₃): δ = 103.3 (C-1^C), 84.2 (C-3^C or C-4^C), 81.6 (C-2^C), 79.3 (C-3^E), 78.2 (C-1^E), 77.3 (C-4^C or C-3^C), 76.7 (C-5^C), 74.5 (C-5^E), 74.3 (C-4^E), 68.6 (C-6^E), 67.1 (C-6^C), 50.6 (CH₂(a)), 29.6 (C-2^E), 10.1 (CH₂(b)), -2.3 (Si(CH₃)₃), benzyl group signals: 138.2 - 137.6 (5 Ar-C'^s), 128.1 - 127.4 (Ar-C'^s), 75.4 (CH₂^{benzyl (a)}), 74.8 (CH₂^{benzyl (b)}), 74.6 (CH₂^{benzyl (c)}), 73.6 (CH₂^{benzyl (d)}), 73.3 (CH₂^{benzyl (e)}), 73.1 (CH₂^{benzyl (f)}). - C₅₉H₇₀INO₁₁SSi (1156.26, 1155.33), FAB MS: *m/z* = 1178.3 ([M+Na]⁺), 1154.2 ([M+H-H₂]⁺), 523.2 ([c]⁺). - HR MS: [M+Na]⁺: calc 1178.3381, found 1178.3380.

3,6-Di-*O*-benzyl-4-*O*-(2,3,4,6-tetra-*O*-benzyl-β-D-glucopyranosyl)-2-deoxy-2-(2-trimethylsilyl)ethanesulfonfylamino)-α-D-glucose (9)

To a solution of **10b** (50 mg, 0.04 mmol) in 2.5:1 THF - H₂O (1.5 mL) at 0°C slowly lithium hydroxide (1 mol/L in water, 65 μl) was added and the mixture was stirred at 0°C for 2 h. Then a further portion of the lithium hydroxide solution (90 μl) was added and the mixture was now stirred at 22°C for 4 h. NH₄Cl (100 mg) was added. After solvent evaporation the residue was extracted with CH₂Cl₂ and the extract filtered through Florisil[®]. After solvent evaporation pure (TLC petrol - ethyl acetate 2:1) **9** (43 mg, 95 %) was obtained. - IR (KBr): 3607 and 3560 - 3200 cm⁻¹ (OH, NH). - ¹H NMR (400 MHz, CDCl₃), characteristic signals: δ = 5.37 - 5.31 (m, after OH→OD exchange: d, J_{1E, 2E} = 3.7 Hz, 1-H^E), 4.49 (d, J_{2E, NH} = 10.3 Hz, NH), 4.46 (d, J_{1C, 2C} ≈ 11.0 Hz, 1-H^C), 3.43 - 3.35 (m, after OH→OD exchange: dd, J_{2E, 3E} = 10.3, 2-H^E), 3.05 (broad s, exchangeable with D₂O), 2.90 - 2.65 (m, CH₂(a)), 0.90 - 0.78 (m, CH₂(b)), -0.21 (s, Si(CH₃)₃). - ¹³C NMR (100.6 MHz, APT, C,H COSY, CDCl₃): δ = 103.1 (C-1^C), 93.0 (C-1^E), 85.3 (CH), 83.2 (CH), 78.5 (CH), 78.0 (CH), 77.2 (CH), 76.1 (CH₂), 75.6 (CH₂), 75.5 (CH₂), 75.3 (CH₂), 73.9 (CH₂), 73.8 (CH₂), 71.2 (CH), 69.4 (CH₂), 68.3 (CH₂), 57.7 (C-2^E), 50.3 (CH₂(a)), 10.4 (CH₂(b)), -1.7 (Si(CH₃)₃), 139.3 - 138.3 (Ar-C'^s), 129.0-128.0 (Ar-C'^s). - C₅₉H₇₁NO₁₂SSi (1046.37, 1045.45), FAB MS: *m/z* = 1068.1 ([M+Na]⁺).

***O*-[3,6-Di-*O*-benzyl-4-*O*-(2,3,4,6-tetra-*O*-benzyl- β -D-glucopyranosyl)-2-deoxy-2-(2-trimethylsilylethane-sulfonylamino)- α -D-glucopyranosyl]-trichloroacetimidate (**11**)**

A solution of **9** (107 mg, 0.1023 mmol), trichloroacetonitrile (102 μ L, 1.02 mmol) and DBU (4 μ L, 0.03 mmol) in CH_2Cl_2 (2 mL) was stirred at 0°C for 3.5 h. Solvent evaporation and FC (petrol - ethyl acetate 8:1 + 1% NEt_3) provided **11** (110 mg, 91 %, TLC: petrol - CHCl_3 - CH_3OH 8:8:0.3), a very sensitive compound for which only a limited set of analytical data could be obtained. - ^1H NMR (200 MHz, CDCl_3), characteristic signals: δ = 8.75 (s, C=NH), 6.45 (broad s, 1- H^E), 3.00 - 2.70 (m, $\text{CH}_2(\text{a})$), 1.10 - 0.80 (m, $\text{CH}_2(\text{b})$), 0.08 (s, $\text{Si}(\text{CH}_3)_3$). - ^{13}C NMR (100.6 MHz, CDCl_3), characteristic signals: δ = 160.8 (C=NH), 103.0 (C-1 C), 96.8 (C-1 E), 85.3, 83.0, 78.4, 76.8, 76.3, 75.4, 75.3, 74.1, 74.0, 69.4, 67.7, 57.0 (C-2 E), 50.6 ($\text{CH}_2(\text{a})$), 10.6 ($\text{CH}_2(\text{b})$), -1.6 ($\text{Si}(\text{CH}_3)_3$), 138.8 - 138.2 (Ar-C' s), 129.2 - 128.1 (Ar-C' s). - $\text{C}_{61}\text{H}_{71}\text{Cl}_3\text{N}_2\text{OSSi}$ (1190.76, 1188.35).

***Allyl 2-O*-[3,6-di-*O*-benzyl-4-*O*-(2,3,4,6-tetra-*O*-benzyl- β -D-glucopyranosyl)-2-deoxy-2-(2-trimethylsilylethanesulfonylamino)-D-glucopyranosyl]-3,4-*O*-isopropylidene- α -D-galacto-pyranosiduronamide (**13**), 1:4 mixture of 1 E - α - and - β -anomers**

A mixture of **11** (50 mg, 0.04 mmol), glycosyl acceptor **12** (16 mg, 0.06 mmol), 4 Å molecular sieves (50 mg), hexane (150 μ L), and CH_2Cl_2 (200 μ L) was stirred at 25°C for 1 h. At -20°C within 2 h TMSOTf (1 mol/L in toluene, 2*9 μ L) was added and the mixture was stirred at 0°C for 2 h. Then triethylamin (25 μ L) was added and the solvents were evaporated. FC (petroleum ether - ethyl acetate 5:1) furnished **13** (33 mg, 60 %) in an α : β ratio of 1:4. IR (KBr): 3600 - 3200 (NH), 1684, 1653, 1636, 1630 cm^{-1} . - ^1H NMR (400 MHz, CDCl_3), only the signals of the β anomer are reported: δ = 7.30 - 7.20 (m, Ar-H) 6.42 (broad s, CONH_2), 5.43 (broad s, CONH_2), 5.01 (d, $J_{1\text{F}, 2\text{F}} = 3.4$ Hz, 1- H^F), 4.84 (d, $J = 11.0$ Hz, 1H), 4.80 - 4.68 (m, 6H), 4.52 - 4.36 (m, 4H), 4.42 - 4.37 (m, 3H), 4.23 (dd, $J_{3\text{F}, 4\text{F}} = 5.4$ Hz, $J_{4\text{F}, 5\text{F}} = 8.3$ Hz, 3- H^F), 4.00 - 3.95 (m, 1H), 3.85 (dd, $J = 8.3$ Hz, $J = 3.5$ Hz, 1H), 3.73 (dd, $J = 8.7$ Hz, $J = 4.6$ Hz, 1H), 3.65 (dd, $J = 10.0$ Hz, $J = 1.5$ Hz, 1H), 3.62 - 3.38 (m, 9H), 3.30 - 3.08 (m, $\text{CH}_2(\text{a})$), 1.40 and 1.30 (2*s, O-C(CH_3) $_2$ -O), 1.05 - 0.80 (m, $\text{CH}_2(\text{b})$), -0.20 ($\text{Si}(\text{CH}_3)_3$), allyl group signals at 5.82 (m, $\text{OCH}_2\text{CH}=\text{CH}_2$), 5.26 (m, 1H of $\text{OCH}_2\text{CH}=\text{CH}_2$), 5.12 (m, 1H of $\text{OCH}_2\text{CH}=\text{CH}_2$), 4.05 (ddt, $\text{OCH}_2\text{CH}=\text{CH}_2$). - ^{13}C NMR (100.6 MHz, APT, C,H COSY, CDCl_3): δ = 170.4 (CONH_2), 109.7 (O-C(CH_3) $_2$ -O), 103.0 (C-1 C), 102.0 (C-1 E), 98.1 (C-1 F), 84.8 (CH), 82.6 (CH), 79.1 (CH), 78.0 (CH), 76.2 (CH), 75.6 (CH), 75.4 (CH), 73.7 (CH), 68.8 (C-6), 68.7 (C-6), 68.3, 57.7 (C-2 E), 50.9 ($\text{CH}_2(\text{a})$), 28.3 and 26.6 (O-C(CH_3) $_2$ -O), 10.2 ($\text{CH}_2(\text{b})$), -1.8 ($\text{Si}(\text{CH}_3)_3$), allyl group signals at 133.3 ($\text{OCH}_2\text{CH}=\text{CH}_2$), 118.2 ($\text{OCH}_2\text{CH}=\text{CH}_2$), 69.6 ($\text{OCH}_2\text{CH}=\text{CH}_2$), benzyl group signals at 138.6 - 138.0 (Ar-C' s), 128.8 - 127.5 (Ar-C' s), 75.6, 75.1, 75.0, 73.3, 72.3 (CH_2). - FAB MS: m/z 1339.5 ($[\text{M}+\text{K}]^+$), 1323.6 ($[\text{M}+\text{Na}]^+$), 1301.6 ($[\text{M}+\text{H}]^+$), 779.1 ($[\text{M}+\text{H}-c]^+$), 523 ($[c]^+$). - $\text{C}_{71}\text{H}_{88}\text{N}_2\text{O}_{17}\text{SSi}$ (1301.63, 1300.56), calc C 65.52, H 6.81, N 2.15, found C 65.40, H 6.82, N 2.19. - HR-MS $[\text{M}+\text{Na}]^+$: calc 1323.5470, found 1323.5490.

Acknowledgements - We wish to thank K.Floeder and S.Hamm for skillful assistance and Dr.M.Lampilas (Roussel Uclaf) for helpful discussions. Financial support by the Deutsche Forschungsgemeinschaft (We 595/22-1 and Innovationskolleg „Chemisches Signal und biologische Antwort“), the Fonds der Chemischen Industrie, Roussel Uclaf, and the Hoechst AG is gratefully acknowledged.

REFERENCES AND NOTES

Dedicated with great admiration to Professor Hans Paulsen on the occasion of his 75th birthday

- 1 Fehlhäber, H.-W.; Girg, M.; Seibert, G.; Hobert, K.; Welzel, P.; van Heijenoort, Y.; van Heijenoort, J. *Tetrahedron* **1990**, *46*, 1557-1568.
- 2 Donnerstag, A.; Marzian, S.; Müller, D.; Welzel, P.; Böttger, D.; Stärk, A.; Fehlhäber, H.-W.; Markus, A.; van Heijenoort, Y.; van Heijenoort, J. *Tetrahedron* **1995**, *51*, 1931-1940.
- 3 Review: Welzel, P. in *Antibiotics and Antiviral Compounds - Chemical Synthesis and Modification* (Eds.: Krohn, K.; Kirst, H.A.; Maag, H.), VCH, Weinheim **1993**, 373-378.
- 4 Lünig, J.; Möller, U.; Müller, D.; Welzel, P.; Markus, A.; van Heijenoort, Y.; van Heijenoort, J. *Tetrahedron* **1993**, *49*, 10587-10596.
- 5 Möller, U.; Hobert, K.; Donnerstag, A.; Wagner, P.; Müller, D.; Fehlhäber, H.-W.; Markus, A.; Welzel, P. *Tetrahedron* **1993**, *49*, 1635-1648.
- 6 van Heijenoort, Y.; Gómez, M.; Derrien, M. F.; Ayala, J.; van Heijenoort, J. *J. Bacteriol.* **1992**, *174*, 3549-3557, and references therein.
- 7 Donnerstag, A.; Hennig, L.; Findeisen, M.; Welzel, P.; Haeßner, R. *Magn. Reson. Chem.*, in the press.
- 8 Scherkenbeck, J.; Hiltmann, A.; Hobert, K.; Bankova, W.; Siegels, T.; Kaiser, M.; Müller, D.; Veith, H. J.; Fehlhäber, H.-W.; Seibert, G.; Markus, A.; Limbert, M.; Huber, G.; Böttger, D.; Stärk, A.; Takahashi, S.; van Heijenoort, Y.; van Heijenoort, J.; Welzel, P. *Tetrahedron* **1993**, *49*, 3091-3100.
- 9 Review: Danishefsky, S. J.; Roberge, J. Y. *Pure Appl. Chem.* **1995**, *67*, 1647-1662.
- 10 Danishefsky, S. J.; Koseki, K.; Griffith, D. A.; Gervay, J.; Peterson, J. M.; McDonald, F. E.; Oriyama, T. *J. Am. Chem. Soc.* **1992**, *114*, 8331-8333.
- 11 Fischer, E.; Zemplén, G. *Ber. Dtsch. Chem. Ges.* **1910**, *43*, 2536-2543.
- 12 Fischer, E.; von Fodor, K. *Ber. Dtsch. Chem. Ges.* **1914**, *47*, 2057-2063.
- 13 Weinreb, S. M.; Demko, D. M.; Lessen, T. A.; Demers, J. P. *Tetrahedron Lett.* **1986**, *27*, 2099-2102.
- 14 Lemieux, R. U.; Morgan, A. R. *Can. J. Chem.* **1965**, *43*, 2190-2198.
- 15 O. Ritzeler, Dissertation, Universität Leipzig **1996**.
- 16 Park, T. K.; Kim, I. J.; Danishefsky, S. J. *Tetrahedron Lett.* **1995**, *36*, 9089-9092, see also Kim, I. J.; Park, T. K.; Hu, S.; Abrampah, K.; Zhang, S.; Livingston, P. O.; Danishefsky, S. J. *J. Org. Chem.* **1995**, *60*, 7716-7717.
- 17 Review: Schmidt, R. R.; Kinzy, W. *Adv. Carbohydr. Chem. Biochem.* **1994**, *50*, 21-117.
- 18 See, Zha, Q.; Bailey, M. D.; Bertrand, M. J. *Can. J. Appl. Spectrosc.* **1990**, *35*, 141-148.
- 19 Still, W. C.; Kahn, M.; Mitra, A. *J. Org. Chem.* **1978**, *43*, 2923-2925.

(Received in Germany 28 October 1996; accepted 29 November 1996)